August 2023 – EMBRN – European Mast Cell and Basophil Research Network

Mast cell silencing: a novel therapeutic approach for urticarial and other mast cell-mediated diseases

Summary Chronic urticaria (CU) is a mast cell (MC)-dependent disease with limited therapeutic options. Current management strategies are directed at inhibiting IgE-mediated activation of MCs and antagonizing effects of released mediators. Due to the complexity and heterogeneity of CU and other MC diseases and mechanisms

August 25, 2023

2B4 – A potential target in Staphylococcus aureus associated allergic inflammation

Summary Staphylococcus aureus (SA) and its exotoxins activate eosinophils (Eos) and mast cells (MCs) via CD48, a GPI-anchored receptor belonging to the Signaling Lymphocytes Activation Molecules (SLAM) family. 2B4 (CD244), an immuno-regulatory transmembrane receptor also belonging to the SLAM family, is the high affinity ligand for

August 25, 2023

European Mast Cell and
Basophil Research Network

Month: August 2023

Mast cell silencing: a novel therapeutic approach for urticarial and other mast cell-mediated diseases

2B4 – A potential target in Staphylococcus aureus associated allergic inflammation

Looking for other posts?

Categories

Archives